Johnson & Johnson (J&J) has halved its expectations for costs this year related to new tariffs and raised its full-year sales ...

Overall venture funding, as well as “first financing” rounds, fell significantly in the second quarter, erasing what had been ...

President Donald Trump's proposed tariffs on pharmaceuticals could lead to higher prices, higher insurance premiums, and even drug shortages, experts say.

In April, Trump announced a 25% tariff on U.S. imports from South Korea as part of his broader “Liberation Day” trade package ...

Consumers picked up their spending in June showing resilience despite anxiety high over tariffs and the U.S. economy.

Novartis AG announced disappointing sales for a key psoriasis drug and the looming retirement of its respected finance chief, ...

Conversations with the Trump administration on its “most favored nation” policy have been productive, the executive said ...

President Trump on Wednesday said he would be sending letters to over 150 countries as he plans a barrage of duties to take ...

Novartis ( NYSE: NVS) CEO Vas Narasimhan said the company has built up its U.S. inventories to help mitigate the impact of ...

Novartis (NVS) raised its full-year profit outlook thanks to strong demand for some of its key drugs. Novartis CEO Vas ...

Novartis stock fell early Thursday after the drugmaker reported light sales of Cosentyx, one of its biggest moneymakers.

Rather than continuing to retaliate with tariffs of its own, the Canadian government has begun to confess that such a tactic ...